Washington Univ Medical School has recv $17 million from Advanced Research Projects Agency for Health to develop an intraarticular therapy using nanoparticles designed to regenerate osteoarthritis damage without any surgical intervention. https://t.co/hl5i3welwS https://t.co/M7LwbIYI88

RheumThoughts: Treatment for Obesity and Inflammation, but at what Cost? The costs of GLP-1 agonists must come down in order to make these treatments available to the people who need them - including many people with rheumatologic diseases. https://t.co/2ltRyallXL https://t.co/tOYwR0LLCj

92 early (<2 yrs) systemic sclerosis pts were treated with #MTX; 79% diffuse SSc. At 3 mos, 34% of dcSSc ≥25% reduction in mRSS - increasing to 612% a@ 24 mos (29% at 24 mos ITT w/ non-responder imputation). GC did not improve skin. Dz progression seen w/ 75% of MTX monoTx D/C https://t.co/WvqyI8GKjT

Physician Perspective: Talking to Patients Regarding Obesity https://t.co/clbg3y9SAu https://t.co/nPEbijPIna

Prescribing New GLP-1-Based Therapies https://t.co/naNfd7B1zA https://t.co/WIi9ZIMH2l

How well do you know the week's news in rheumatology? RheumIQ Emails are becoming opt-in only Get the quiz by email Log in to receive each new case-based quiz directly in your inbox. https://t.co/i04scCX31o https://t.co/vV88xXfQ6W

Are Concerns Over Avacopan Efficacy Overblown? Avacopan (Tavneos), the complement pathway inhibitor for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), appeared strongly effective in an Italian registry study, maybe a step toward putting questions about https://t.co/4w2INKPFeT

EADV abstract showed daxdilimab (anti-ILT7; on plasmacytoid dendritic cells) was effective in mod-severe discoid lupus. Ph II RCT 72 refract. DLE RCT; DAX vs PBO - ↓ CLASI-A vs placebo @24 wks. wk 4 ≥50% CLASI-A ~62% vs 24% https://t.co/gJ4drxErGD https://t.co/TexG55dDBL

Symptomatic hand OA (HOA) increased signif in past decade in the Netherlands (esp women & older adults). PCP EHR study of 1.8 million Dutch patients ≥30 yrs. Betw 2013 & 2023, prevalence incr 65% (5.7 to 9.4%); incidence rose 20% (7.1 to 8.5/1000PY) https://t.co/HyqdwJ70y4 https://t.co/CU0NGccI3k

Singapore center study of 119 IIM pts (DM 57%; ASyS 23%, OM 15%), IMNM 4%). MDA5 Abs seen in 35% DM. Vs ASyS, MDA5-DM had signif more Skin Sxs (ulcers, papules, Gottrons, heliotrope, periungual erythema). MSK Sxs equal & higher CK levels in ASyS MDA5. 79% DM-ILD were MDA5+ https://t.co/hWaaeLUYkz

On this week's podcast, Dr. Jack Cush reviews the news: Steroids are easy to start and hard to stop; hold the MTX but not the biologic or JAK, weighing in on avacopan, and age-old messages for old-age patients. 🎧 Read + listen: https://t.co/kK8WKgIxYT and subscribe wherever you https://t.co/xGTXyuRJU8

Ann Int Med report - 1/3 of advanced practice registered nurses trained at for-profit programs (CA 41%, FL 35%, TX 21%, IO 15%), up from just 2.4% in 2010. Estimated 1 APRN for every 2.2 physicians. 35% projected growth over the next decade (vs 3% growth for MDs) https://t.co/7vkB5yeLNR

Univ Toronto lupus clinic study of 165 #SLE pts w/ Bx-proven LN (age 35.3 yrs; Dz dur 6.2 years). Half on antimalarial Rx. Being on HCQ did not alter Renal Bx outcomes (prolif GN, NIH AI, NIH CI, IFTA score. (But is known to improve renal outcomes) https://t.co/oQ0CgK7rXm https://t.co/cJMMVFmLcy

An important pitch and resource for training and careers at the NIH - National Institute of Arthritis and Musculoskeletal and Skin Diseases https://t.co/JhU1zbVunF https://t.co/uIf5U2dXoC